# China NMPA Product Recall - Single Photon Emission Tomography (SPECT)

Source: https://www.globalkeysolutions.net/records/china_product_recall/ge-medical-systems-israel-functional-imaging/a96072ed-4065-48a6-b35c-1eb8f0e1b559/
Source feed: China

> China NMPA product recall for Single Photon Emission Tomography (SPECT) by GE Medical Systems Israel, Functional Imaging published February 01, 2019. Recall level: Level 2 Recall. GE Medical Systems Israel, Functional Imaging, a manufacturer of medical devices, initiated a Class 

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: GE Medical Systems Israel, Functional Imaging, is proactively recalling its SPECT (Single Photon Emission Tomography) scanner.
- Company Name: GE Medical Systems Israel, Functional Imaging
- Publication Date: 2019-02-01
- Product Name: Single Photon Emission Tomography (SPECT)
- Recall Level: Level 2 Recall
- Recall Reason: A very small number of SPECT (Discovery NM530c) single-photon emission computed tomography (SPECT) devices have not installed the latest software.
- Discovering Company: GE Healthcare Systems Trade Development (Shanghai) Co., Ltd.
- Manufacturing Company: GE Medical Systems Israel, Functional Imaging
- Summary: GE Medical Systems Israel, Functional Imaging, a manufacturer of medical devices, initiated a Class II voluntary recall of its SPECT single-photon emission computed tomography device (model Discovery NM 530c). The recall, reported to China's National Medical Products Administration (NMPA) under the regulatory framework of CFDA (Imported) 2010 No. 3332673, stems from a critical issue where a small number of these devices were not equipped with the latest software. The primary concern is the potential impact on the product's intended use for nuclear medicine imaging examinations, particularly in cardiac diagnostics, which relies on accurate uptake detection of radioactive isotope tracers. While the manufacturer, through its agent GE Healthcare Systems Trading Development (Shanghai) Co., Ltd., identified this software deficiency, it confirmed that none of the affected batches were sold within China. Consequently, the required action for the Chinese market was limited to a formal report to the NMPA on January 24, 2019, informing them of the potential problem and GE Healthcare's global plan to correct all affected systems. This proactive disclosure ensures regulatory transparency even when local sales are unaffected.

Company: https://www.globalkeysolutions.net/companies/ge-medical-systems-israel-functional-imaging/623a1a57-794e-48ac-a754-e079c5e2ad13/